Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Technology Venture Capital Trust Plc LSE:OXT London Ordinary Share GB0006640204 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 28.00 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
18.00 38.00 28.00 28.00 28.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial -0.04 -0.70 2
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 28.00 GBX

Oxford Technology Ventur... (OXT) Latest News

More Oxford Technology Ventur... News
Oxford Technology Ventur... Takeover Rumours

Oxford Technology Ventur... (OXT) Discussions and Chat

Oxford Technology Ventur... Forums and Chat

Date Time Title Posts
24/7/202010:26Oxford Technology VCT with Charts & News49
19/8/200514:35Oxford Technology3

Add a New Thread

Oxford Technology Ventur... (OXT) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Oxford Technology Ventur... trades in real-time

Oxford Technology Ventur... (OXT) Top Chat Posts

Oxford Technology Ventur... Daily Update: Oxford Technology Venture Capital Trust Plc is listed in the General Financial sector of the London Stock Exchange with ticker OXT. The last closing price for Oxford Technology Ventur... was 28p.
Oxford Technology Venture Capital Trust Plc has a 4 week average price of 0p and a 12 week average price of 28p.
The 1 year high share price is 35p while the 1 year low share price is currently 28p.
There are currently 5,431,655 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Oxford Technology Venture Capital Trust Plc is £1,520,863.40.
127tolmers: SCANCELL COULD BE THE NEXT BIG BENEFICIARY OF THE SPATE OF LICENSING DEALS ....... Matthew Goodman in this week's Sunday Times suggests Scancell could be the next big beneficiary of the spate of licensing deals currently being struck in the super hot area of Cancer Immunotherapy: "There are likely to be further deals struck as the pharma giants strive to boost their exposure to this rapidly expanding market. Scancell, an AIM-listed company that is developing melanoma vaccines, is set to begin a search for a bigger partner to help fund late-stage trials of its treatments after publishing encouraging data last month. "We are looking at 2014 as the year we consummate a relationship or a deal to take this forward," said Richard Goodfellow, Scancell's joint chief executive. Most drug companies are also looking into how different immunotherapies could work in tandem with existing cancer treatments." Is this the trigger for the OXT price reversal?
Oxford Technology Ventur... share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Oxford Tec..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200815 17:29:23